Study Review – aclidinium bromide versus tiotropium and placebo in COPD

This review summarises and discusses a recent publication on a post-hoc analysis of the bronchodilatory
efficacy and chronic obstructive pulmonary disease (COPD) symptom reduction findings of a novel long-acting
anticholinergic antagonist, aclidinium bromide (henceforth referred to as aclidinium), compared to tiotropium and
placebo, in symptomatic patients with COPD. 

Independent expert commentary provided by Dr Greg King, who is a respiratory physician at the
Royal North Shore Hospital, The Woolcock Institute of Medical Research and Northern Clinical School, University of Sydney. 

Please login below to download this issue (PDF)